AprilBio Largest Shareholder Change Finalized, Control Transferred to IMM Consortium with Large Capital Increase Raising Dilution Concerns
This disclosure finalizes the change in AprilBio's largest shareholder from former CEO Cha Sang-hoon and two others to IMM Healthcare No. 8 LLC and two others, resulting from the execution of a share purchase agreement and completion of a third-party allotment capital increase.
The new largest shareholder and its affiliates will hold a total of 5,981,862 shares representing 19.22% ownership. The capital increase issues 7,704,051 new shares, causing approximately 33% dilution relative to existing shares. Among the new shares, 8,926,305 shares including 1,222,254 non-voting convertible preferred shares will be subject to a one-year lock-up.
Part of the acquisition funds were raised through debt: IMM Healthcare No. 8 borrowed 48 billion won from TKG Taekwang on a short-term basis, and IMM Scale-up Bio No. 1 borrowed 40 billion won from Shinhan Investment Corp with a 5-year maturity. The acquired shares serve as collateral for the loans.
Management rights will be exercised by TKG Huchens under a joint investment agreement, indicating a shift in control from existing management to industrial capital. The new largest shareholder is a special purpose company established in July 2026 under the Capital Market Act.
[AI Summary]The change in AprilBio's largest shareholder is a leveraged buyout accompanied by a large capital increase, posing significant dilution risk to existing shareholders. The high reliance on debt financing and short-term borrowing raise financial stability concerns. While the stock price may face short-term negative pressure, the involvement of TKG Huchens could create long-term business synergies.